AAMU
PBYI icon

Amundi Asset Management US’s Puma Biotechnology PBYI Stock Holding History

Amundi Asset Management US’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,449
Closed -$119K – 1640
2020
Q2 		$119K Hold
11,449
– – ﹤0.01% 1429
2020
Q1 		$97K Buy
+11,449
New +$111K ﹤0.01% 1437
2019
Q1 		– Sell
-3,000
Closed -$61K – 1677
2018
Q4 		$61K Buy
+3,000
New +$90K ﹤0.01% 1544
2014
Q2 		– Sell
-30,901
Closed -$3.22M – 640
2014
Q1 		$3.22M Buy
+30,901
New +$3.63M 0.01% 515

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Amundi Asset Management US's PBYI Position: Q3 2020 in Review

Amundi Asset Management US sold out of Puma Biotechnology (PBYI) in Q3 2020, closing a stake of 11,449 shares — an estimated $119K sold.

Amundi Asset Management US first reported a position in PBYI in Q1 2014 and held it in 4 quarters. The position peaked at $3.22M in Q1 2014. 128 funds tracked by Wall St. Rank hold PBYI as of Q3 2020.

  • Amundi Asset Management US reported no remaining Puma Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 11,449 Puma Biotechnology shares in Q3 2020, an estimated $119K.
  • Amundi Asset Management US first reported a position in Puma Biotechnology in Q1 2014 and held it in 4 quarters.
  • Amundi Asset Management US's Puma Biotechnology position peaked at $3.22M in Q1 2014.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2020.

Based on Amundi Asset Management US's 13F filing for Q3 2020, filed 16 Nov 2020.